This piece from Xconomy examines where the next generation of biotech blockbusters will come from relative to bio clusters (or elsewhere) in the US. The article was speculating whether San Francisco would retain its perceived dominant position - you should read the article in full.
The qualifications a molecule needed to meet to be considered, included: completion of a pivotal trial, and have either received FDA approval or are clearly on that path. The 8 nominees using that criteria:
- Human Genome Sciences' lupus drug (Benlysta)
- Vertex Pharmaceuticals drugs for hepatitis c (telaprevir) and cystic fibrosis (VX-770)
- Dendreon's prostate cancer drug (Provenge)
- Seattle Genetic's rare lymphoma empowered antibody (SGN-35 or brentuximab vedotin)
- Amgen's antibody (denosumab) for osteoporosis (Prolia) and cancer (Xgeva)
- Plexxicon and Roche's melanoma treatment (PLX-4032)
- Genetech/Roche's empowered Herceptin (T-DM1)
That's one from Washington DC, two from Boston, two from Seattle, one from greater LA, and two from the San Francisco bay. Over and out.